CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Q1 2025 vs. Q4 2024
How the institutions holding CRISPR Therapeutics AG changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 406 | 4 | 398 | −4 |
| Shares | 64.6M | 1.10K | 64.7M | +106.8K (+0.2%) |
| Value | $2.54B | $43.5K | $2.20B | −$339.4M (−13.3%) |
4 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (55)
Institutions that held CRISPR Therapeutics AG at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (59)
Institutions that held CRISPR Therapeutics AG at the end of Q4 2024 and filed for Q1 2025 without it.
Not filed for Q1 2025 yet (4)
Institutions that held CRISPR Therapeutics AG at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Global Retirement Partners, LLC | 984 | $38.7K |
| Oliver Lagore Vanvalin Investment Group | 75 | $2.95K |
| WR Wealth Planners, LLC | 42 | $1.65K |
| Legacy Investment Solutions, LLC | 4 | $159 |